as of 11-20-2026 3:45pm EST
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
| Founded: | 1987 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN 4 |
| Market Cap: | 7.8B | IPO Year: | 2012 |
| Target Price: | $57.74 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Buy | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.30 | EPS Growth: | -34.10 |
| 52 Week Low/High: | $27.00 - $55.67 | Next Earning Date: | 11-03-2026 |
| Revenue: | $1,475,899,000 | Revenue Growth: | -5.25% |
| Revenue Growth (this year): | 23.6% | Revenue Growth (next year): | 5.69% |
| P/E Ratio: | -154.00 | Index: | |
| Free Cash Flow: | 480.3M | FCF Growth: | -53.68% |
EVP, CLO, Alkermes, Inc.
Avg Cost/Share
$46.17
Shares
2,035
Total Value
$93,955.95
Owned After
219,353
SEC Form 4
EVP, CLO, Alkermes, Inc.
Avg Cost/Share
$48.01
Shares
2,034
Total Value
$97,652.34
Owned After
219,353
SEC Form 4
EVP R&D, Chief Medical Officer
Avg Cost/Share
$46.99
Shares
9,000
Total Value
$422,874.00
Owned After
65,389
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Gaffin David Joseph | ALKS | EVP, CLO, Alkermes, Inc. | Nov 3, 2026 | Sell | $46.17 | 2,035 | $93,955.95 | 219,353 | |
| Gaffin David Joseph | ALKS | EVP, CLO, Alkermes, Inc. | Sep 3, 2026 | Sell | $48.01 | 2,034 | $97,652.34 | 219,353 | |
| Hopkinson Craig C. | ALKS | EVP R&D, Chief Medical Officer | Sep 1, 2026 | Sell | $46.99 | 9,000 | $422,874.00 | 65,389 |
SEC 8-K filings with transcript text
Nov 3, 2026 · 100% conf.
1D
-0.44%
$46.09
Act: +0.44%
5D
-4.24%
$44.33
20D
-3.39%
$44.72
2 alks-ex99_1.htm
Exhibit 99.1
Alkermes Contacts:
For Investors:
Sandy Coombs +1 781 609 6377
For Media:
Katie Joyce +1 781 249 8927
Alkermes plc Reports Third Quarter 2026 Financial Results
— Third Quarter Revenues of $480.1 Million —
— GAAP Net Income of $16.3 Million and Adjusted EBITDA of $120.1 Million —
— Company Reiterates 2026 Financial Expectations —
DUBLIN, Nov. 3, 2026 — Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2026.
“We delivered solid commercial and financial performance in the third quarter while continuing to advance our portfolio of orexin 2 receptor agonists in central disorders of hypersomnolence and other neuropsychiatric conditions,” said Blair Jackson, President and Chief Executive Officer of Alkermes. “The rapid expansion of our orexin development programs, highlighted by our recent clinical proof-of-concept data in ADHD and initiation of a phase 2 study in major depressive disorder, further strengthens our leadership position in orexin-based research. As we continue to advance our orexin development portfolio, we are growing the body of evidence supporting the potential of orexin biology across multiple neuropsychiatric disorders and expect several important clinical data readouts over the year ahead. With a portfolio of development candidates in one of the most exciting new therapeutic categories in neuroscience and a steady cadence of clinical data readouts ahead, we believe we are well positioned to drive long-term value for shareholders.”
Key Financial Highlights
Revenues
Three Months Ended
September 30,
Nine Months Ended
September 30,
(In millions)
2026
2025
2026
2025
Total Revenues
$
480.1
$
394.2
$
1,369.1
$
1,091.4
Total Proprietary Net Sales
$
417.3
$
317.4
$
1,167.1
$
869.2
$
127.6
$
121.1
$
364.4
$
343.8
ARISTADA®i
$
103.9
$
98.1
$
294.4
$
272.8
$
95.9
$
98.2
$
282.2
$
252.6
$
89.9
$
—
$
226.0
$
—
Profitability
Three Months Ended
September 30,
Nine Months Ended
September 30,
(In millions)
2026
2025
2026
2025
GAAP Net Income (Loss)
$
16.3
$
82.8
$
(49.7)
$
192.3
$
63.0
$
96.9
$
81.8
$
221.2
Adjusted EBITDA
$
120.1
$
121.5
$
339.5
$
293.7
Revenue Highlights
Proprietary Product Revenues
• VIVITROL revenues for the quarter were $127.6 million. During the quarter, the company recorded VIVITROL revenue of approximately $8 million related to gross-to-net favorability, primarily driven by favorable patient mix.
1
• ARISTADAi revenues for the quarter were $103.9 million, which included approximately $4 million of inventory benefit related to timing of shipments. During the quarter, the company recorded ARISTADA revenue of approximately $3 million related to gross-to-net favorability, primarily driven by favorable patient mix.
• LYBALVI revenues for the quarter were $95.9 million, which included approximately $2 million of inventory benefit related to timing of shipments. Total prescriptions grew 18% compared to the third quarter of 2025.
• LUMRYZ revenues for the quarter were $89.9 million. At the end of the third quarter, approximately 4,100 patients were on LUMRYZ therapy.
Manufacturing & Royalty Revenues
• VUMERITY® manufacturing and royalty revenues for the quarter were $29.5 million.
• Royalty revenue from XEPLION®, INVEGA TRINZA®/TREVICTA® and INVEGA HAFYERA®/BYANNLI® for the quarter were $26.4 million.
Key Operating Expenses
Three Months Ended
September 30,
(In millions)
2026
2026
Transaction Adjustments
2026
Non-GAAP
Adjusted
2025
Cost of Goods Sold
$
94.2
$
28.7
$
65.6
$
51.6
R&D Expense
$
121.1
$
0.1
$
121.0
$
81.7
SG&A Expense
$
208.5
$
1.0
$
207.5
$
171.8
Nine Months Ended
September 30,
(In millions)
2026
2026
Transaction Adjustments(1)
2026
Non-GAAP
Adjusted
2025
Cost of Goods Sold
$
253.9
$
72.4
$
181.5
$
150.2
R&D Expense
$
337.4
$
8.3
$
329.1
$
230.9
SG&A Expense
$
690.7
$
57.6
$
633.1
$
514.3
(1) Includes $20.2 million of share-based compensation expense related to the acceleration of vesting of equity awards for former Avadel Pharmaceuticals plc (Avadel) employees which vested in full upon the closing of the transaction.
Balance Sheet
• At Sept. 30, 2026, the company recorded cash, cash equivalents and total investments of $787.6 million, compared to $691.6 million at June 30, 2026.
Financial Expectations for 2026
Alkermes reiterates its financial expectations for 2026, as set forth in its press release dated July 28, 2026.
Conference Call
Alkermes will host a conference call and webcast presentation with accompanying slides at 8:00 a.m. ET (1:00 p.m. GMT) on Tuesday, November 3, 2026, to discuss these financial results and provide an update on the company. The webcast may be accessed on the Investors section of Alkermes’
Jul 28, 2026 · 100% conf.
1D
+1.23%
$52.48
Act: -4.28%
5D
+3.91%
$53.87
20D
+5.80%
$54.85
2 alks-ex99_1.htm
Exhibit 99.1
Alkermes Contacts:
For Investors:
Sandy Coombs +1 781 609 6377
For Media:
Katie Joyce +1 781 249 8927
Alkermes plc Reports Second Quarter 2026 Financial Results
— Second Quarter Revenues of $496.0 Million —
— GAAP Net Income of $0.5 Million and Adjusted EBITDA of $139.2 Million —
— Blair Jackson to Assume Chief Executive Officer Role on August 1, 2026; Richard Pops to Continue as Chairman of the Board of Directors —
DUBLIN, July 28, 2026 — Alkermes plc (Nasdaq: ALKS) today reported financial results for the second quarter of 2026.
“The second quarter was marked by strong commercial performance and meaningful progress across our pipeline as we continued to execute on our strategic priorities. Our commercial portfolio consists of differentiated products that are positioned to generate substantial revenue and cash flow for years to come. At the same time, our orexin 2 receptor agonist portfolio represents a potentially transformational growth opportunity for Alkermes and positions us at the forefront of one of the most exciting new therapeutic categories in neuroscience,” said Richard Pops, Chairman and Chief Executive Officer of Alkermes. “As I prepare to transition the Chief Executive Officer role, I do so with tremendous pride in what this organization has achieved and great optimism for its future. Blair and the leadership team are well positioned to build on this momentum and lead Alkermes through its next phase of growth, innovation and value creation, and I look forward to supporting them in my continuing role as Chairman.”
“As we move into the second half of the year, we have clear priorities and a sharp focus on execution. With our first ADHD data for ALKS 7290 expected in the coming months and topline results from our alixorexton phase 2 idiopathic hypersomnia study expected toward year-end, we are generating significant new datasets that may open new opportunities for our orexin 2 receptor portfolio,” said Blair Jackson, Chief Operating Officer of Alkermes. “With a talented team, a strong financial foundation and exciting opportunities ahead in sleep medicine and across our neuroscience portfolio, I am honored to step into the CEO role and continue building on the strong foundation for growth that Richard and the entire organization have established.”
Key Financial Highlights
Revenues
Three Months Ended
June 30,
Six Months Ended
June 30,
(In millions)
2026
2025
2026
2025
Total Revenues
$
496.0
$
390.7
$
888.9
$
697.2
Total Proprietary Net Sales
$
411.7
$
307.2
$
749.8
$
551.7
$
124.5
$
121.7
$
236.9
$
222.7
ARISTADA®i
$
96.7
$
101.3
$
190.5
$
174.8
$
94.0
$
84.3
$
186.3
$
154.3
$
96.6
$
—
$
136.1
$
—
Profitability
Three Months Ended
June 30,
Six Months Ended
June 30,
(In millions)
2026
2025
2026
2025
GAAP Net (Loss) Income
$
0.5
$
87.1
$
(66.0)
$
109.6
$
49.0
$
101.6
$
18.8
$
124.3
Adjusted EBITDA
$
139.2
$
126.5
$
219.5
$
172.1
1
Revenue Highlights
Proprietary Product Revenues
• LYBALVI revenues for the quarter were $94.0 million. Revenues and total prescriptions grew 12% and 18%, respectively, compared to the second quarter of 2025.
• ARISTADAi revenues for the quarter were $96.7 million. During the quarter, the company recorded ARISTADA revenue of approximately $4 million related to gross-to-net favorability, primarily driven by favorable patient mix.
• VIVITROL revenues for the quarter were $124.5 million. During the quarter, the company recorded VIVITROL revenue of approximately $4 million related to gross-to-net favorability, primarily driven by favorable patient mix.
• LUMRYZ revenues for the quarter were $96.6 million, which included approximately $7 million of inventory benefit due to timing of shipments.
Manufacturing & Royalty Revenues
• VUMERITY® manufacturing and royalty revenues for the quarter were $30.6 million.
• Royalty revenue from XEPLION®, INVEGA TRINZA®/TREVICTA® and INVEGA HAFYERA®/BYANNLI® for the quarter were $27.5 million.
• Manufacturing revenue from RISPERDAL CONSTA® for the quarter was $20.9 million.
Key Operating Expenses
Three Months Ended
June 30,
(In millions)
2026
2026
Transaction Adjustments
2026
Non-GAAP
Adjusted
2025
Cost of Goods Sold
$
98.1
$
31.0
$
67.1
$
49.5
R&D Expense
$
112.9
$
0.1
$
112.8
$
77.4
SG&A Expense
$
217.6
$
1.3
$
216.3
$
170.8
Six Months Ended
June 30,
(In millions)
2026
2026
Transaction Adjustments(1)
2026
Non-GAAP
Adjusted
2025
Cost of Goods Sold
$
159.7
$
43.8
$
115.9
$
98.7
R&D Expense
$
216.3
$
8.2
$
208.1
$
149.2
SG&A Expense
$
482.2
$
56.6
$
425.6
$
342.6
(1) Includes $20.2 million of share-based compensation expense related to the acceleration of vesting of equity awards for former Avadel Pharmaceuticals plc (Av
May 5, 2026 · 100% conf.
1D
+1.70%
$36.87
Act: -2.57%
5D
+3.70%
$37.59
Act: +5.63%
20D
+4.28%
$37.80
Act: +17.96%
SEC.gov | Request Rate Threshold Exceeded
U.S. Securities and Exchange Commission
You’ve Exceeded the SEC’s Traffic Limit
Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.
Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.
The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.
For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.
For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.
Reference ID: 0.c706d217.1784470094.ec62c2a1
More Information
Internet Security Policy
By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.
Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).
To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.
Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.
Note: We do not offer technical support for developing or debugging scripted downloading processes.
See how ALKS stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "ALKS Alkermes plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.